Market Herald logo

Subscribe

Be the first with the news that moves the market
  • Psyched Wellness (PSYC) has selected ShipHero as its eCommerce fulfillment partner for Calm and future products
  • ShipHero is a tech-enabled 3PL that offers simple, fast, and affordable fulfillment for thousands of brands across the U.S., Canada, Europe and Australia
  • Psyched Wellness is a Canadian-based health supplements company dedicated to the distribution of mushroom-derived products
  • Psyched Wellness Ltd. (PSYC) opened trading at C$0.12

Psyched Wellness (PSYC) has selected ShipHero as its eCommerce fulfillment partner for Calm and future products in the company’s innovation pipeline.

ShipHero is a tech-enabled 3PL that offers simple, fast, and affordable fulfillment for thousands of brands with international fulfillment networks across the United States, Canada, Europe, and Australia.

Psyched Wellness Chief Commercial Officer, Matthew Singh, commented on the partnership with ShipHero.

“We are excited to work with a company as advanced as ShipHero. Our priority is ensuring the customer purchase and delivery experience is positive and seamless. ShipHero’s advanced platform will allow us to optimize every aspect of our fulfillment journey. Their wide-spread infrastructure will allow us to ship quickly and efficiently while their pre-existing integration with our eCommerce vendor platform will allow us to stay informed as our product begins shipping throughout the United States. They are a logistics partner that will allow Psyched Wellness to grow and scale as our product demand continues to increase.”

Psyched Wellness is a Canadian-based health supplements company dedicated to the distribution of mushroom-derived products and associated consumer packaged goods.

Psyched Wellness Ltd. (PSYC) opened trading at C$0.12.


More From The Market Herald

" Lobe Sciences (CSE:LOBE) incorporates Australian subsidiary for psilocin trials

Lobe Sciences (LOBE) has incorporated its wholly-owned Australian subsidiary to facilitate three or more clinical trials.

" Origin Therapeutics’ (CSE:ORIG) Xpira Pharmaceuticals receive FDA approval for psilocybin

Origin Therapeutics’ (ORIG) company, Xpira Pharmaceuticals, receives FDA approval for psilocybin for a trial IND application.
Numinus Wellness - Founder & CEO, Payton Nuquvest

" Numinus (TSX:NUMI) expands ketamine therapy

Numinus Wellness (NUMI) announced the opening of a new clinic in Montreal that will replace an existing downtown clinic.

" Optimi Health (CSE:OPTI), ATMA Journey Centres to proceed with Phase I natural psilocybin and MDMA clinical trial application to Health Canada

Optimi Health (OPTI) has confirmed its intent to proceed with a Phase I clinical trial application (CTA).